Clin Cancer Res: Venetok plus azacitidine for AML with low cytogenetic risk

The biology of acute myeloid leukemia (AML) changes with age; Older adults have a higher incidence of low-risk cytogenetics, including partial or complete loss of chromosomes 5 or 7 and the presence of

The study assessed the efficacy and safety

The researchers analyzed data

127 patients at low cytogenetic risk were treated with vinetok + azacitidine (TP53 wild-type 53, TP53-mutant 54-bit) compared

For patients at low cytogenetic risk of TP53 mutation, vinetok + azacitidine monotherapy improved the compound response rate (41% vs 17%), with median DoR of 6.

Patients with grade 3 and above of TP53 mutations in the Venetok + Azacitine and Azacitine single-agent groups had febrile neutropenia (55% vs 39%), thrombocytopenia (28% vs 28%), neutropenia (26% vs 17%), anemia (13% vs.

In summary, compared with azacitine alone, Vinetok plus azacitine increased the compound remission rate in patients with AML with a low cytogenetic risk of TP53 mutation, but did not prolong the duration of remission and overall survival

Original Source:

Daniel A.